Ameritas Investment Partners Inc. Has $2.42 Million Position in Neurocrine Biosciences, Inc. $NBIX

Ameritas Investment Partners Inc. lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,215 shares of the company’s stock after selling 402 shares during the period. Ameritas Investment Partners Inc.’s holdings in Neurocrine Biosciences were worth $2,415,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Cetera Investment Advisers increased its position in shares of Neurocrine Biosciences by 45.1% in the 1st quarter. Cetera Investment Advisers now owns 11,857 shares of the company’s stock valued at $1,311,000 after buying an additional 3,688 shares in the last quarter. TD Asset Management Inc grew its stake in Neurocrine Biosciences by 21.0% in the first quarter. TD Asset Management Inc now owns 123,183 shares of the company’s stock valued at $13,624,000 after acquiring an additional 21,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Neurocrine Biosciences by 87.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 114,765 shares of the company’s stock worth $12,693,000 after acquiring an additional 53,505 shares in the last quarter. Sheaff Brock Investment Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 4.8% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 2,619 shares of the company’s stock worth $290,000 after acquiring an additional 120 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Neurocrine Biosciences by 55.9% during the first quarter. Mackenzie Financial Corp now owns 86,109 shares of the company’s stock worth $9,524,000 after purchasing an additional 30,888 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on NBIX shares. Zacks Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Stifel Nicolaus upped their price target on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Piper Sandler increased their price objective on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $170.53.

Insider Activity

In other news, CEO Kyle Gano sold 300 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $19,933,581.79. This represents a 0.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the transaction, the director owned 40,360 shares of the company’s stock, valued at $6,127,455.20. The trade was a 30.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Stock Up 1.6%

Shares of NBIX opened at $143.53 on Wednesday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.67. The stock has a market capitalization of $14.31 billion, a P/E ratio of 34.34, a P/E/G ratio of 0.94 and a beta of 0.22. The company has a 50 day moving average of $142.44 and a 200-day moving average of $134.35.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. The business had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 earnings per share. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.